We also present the first report of an exploratory subgroup analysis of entrectinib in patients with ROS1 fusion-positive NSCLC who had not received any prior systemic therapy in the metastatic setting (first-line population). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.